Formulary Watch
Latest News
All News
Advertisement
The vaccines advisory committee voted late on Friday, September 17, 2021, to provide emergency authorization of Pfizer’s COVID-19 vaccine as a booster for those over the age of 65, as well as for those at high risk of developing severe disease.
Rinvoq achieved primary and secondary end points compared with placebo.
To date, Pfizer has not received reports of adverse events related to this recall, but is making the move as a precaution.
The combination of bamlanivimab/etesevimab can now be given to both treat and prevent COVID-19 infection after exposure.
Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.
Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations. This is the second approval for this mutation and the first oral therapy.
The FDA has set a Prescription Drug User Fee Act target action date of April 30, 2022.
The agency has granted accelerated approval to Brukinsa as a second-line treatment for patients with marginal zone lymphoma, a group of slow-growing non-Hodgkin lymphomas.
The plan will cover administration of the booster for those with cancer or who are immunocompromised.
Advertisement
Alinia and Sutent have been removed from the drug lists because of the introduction of generic therapies.
Real-world data show Erleada prolonged survival in both metastatic and non-metastatic castration-sensitive prostate cancer.
The affected lots of this rare disease therapy have been contaminated with yeast, mold, and bacteria, which could lead to life-threatening infections.
The PDUFA date has been set for July 12, 2022.
Jardiance demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure.
Officials with OptumRx predict four new therapies that are expected to an impact on patients and on the market.
Point32Health is the name of the not-for-profit health care organization formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan.
Investigators found patients with COPD taking Anoro Ellipta had low overall on-treatment exacerbation rates, which can reduce medical costs due to increased adherence to therapy.
The lot contains kits with the incorrect solution for diluting vancomycin, which could lead to doses above or below recommended levels.
Investigators find there is strong adherence soon after patients fill prescriptions but less consistent use after initial treatment.
ICER’s updated analysis uses observational, real-world data for three therapies — Takhzyro, Haegarda, and Cinryze.
The therapy, to be launched in October, is delivered quickly to the bloodstream by targeting the upper nasal space.
The CDC and the FDA have updated their recommendations for the 2021-2022 flu season.
American Academy of Sleep Medicine’s guideline recommends Wakix to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
CMS negotiates a 70% discount for Ozempic and Wegovy
2
Virtual care replaces, not adds, Medicare visits for health systems, analysis shows
3
Optum Rx removes reauthorizations from an additional 40 drugs
4
FDA approves $2.59 million gene therapy for SMA
5
